Acknowledgements

The ESUR-SBUR organising committee is very grateful for the support of the following companies:

Bladder-Cancer-Journal-banner-200

 

Eepitome-logo-200

 

MDX-logo-200

MDxHealth is a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment. The company’s tests are based on proprietary gene methylation (epigenetics) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy.